BRANFORD, Conn.–(BUSINESS WIRE)–Nov. 13, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has been awarded Frost & Sullivan’s prestigious 2024 Technology Innovation Leadership Award in North America. This award recognizes QSI’s groundbreaking work in developing the Platinum® instrument, the first benchtop sequencer capable of providing […]

Published Preprint Demonstrates Platinum’s Capability to Discriminate Peptide Variants with Single Amino Acid Resolution BRANFORD, Conn.–(BUSINESS WIRE)–Nov. 7, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a newly released preprint publication on BioRxiv, from Dr. Gloria Sheynkman at the University of Virginia School of Medicine. In the […]

BRANFORD, Conn.–(BUSINESS WIRE)–Nov. 5, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in two upcoming investment conferences. Jeff Hawkins, Quantum-Si’s Chief Executive Officer, will participate in a fireside chat discussion at the UBS Global Healthcare Conference on Wednesday, November 13th, at 8:45 […]

“From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si’s Next-Generation Protein Sequencing™ Technology” BRANFORD, Conn.–(BUSINESS WIRE)–Oct. 30, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced its attendance at the 2024 American Society of Human Genetics (ASHG) Annual Meeting, where it will host a sponsored talk on the […]

BRANFORD, Conn.–(BUSINESS WIRE)–Oct. 23, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter of 2024 on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results and provide a business update on the […]

BRANFORD, Conn.–(BUSINESS WIRE)–Oct. 17, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted an aggregate of 385,983 restricted stock units (“RSUs”) to five new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, […]

BRANFORD, Conn.–(BUSINESS WIRE)–Oct. 10, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced its participation at the Human Proteome Organization (HUPO) World Congress 2024 in Dresden, Germany. As a leader in Next-Generation Protein Sequencing™ (NGPS), Quantum-Si will be joined by prominent researchers to present data showcasing advancements in […]

BRANFORD, Conn.–(BUSINESS WIRE)–Sep. 24, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced an upcoming webinar that will explore the integration of top-down mass spectrometry (TD-MS) with Quantum-Si’s groundbreaking Platinum® instrument. The event, titled “Integrating Top-Down Mass Spectrometry and Single-Molecule Sequencing for Proteoform Analysis,” will take place on […]

BRANFORD, Conn.–(BUSINESS WIRE)–Sep. 19, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024. Quantum-Si’s management team will provide updates on the Company’s market opportunities, provide deeper insights into the technology […]

BRANFORD, Conn.–(BUSINESS WIRE)–Sep. 4, 2024– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™ (“NGPS”) into their platform for developing novel gene therapies with improved targeting […]